Table 4.
Entry | Name | R1 | R2 | R3 | X | KOR 1 % | MOR 1 % | DOR 1 % | BZR 1 % |
KOR (Ki, nM) |
BZR (Ki, nM) |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | SH-I-85 | Br | H | H | C-F | 91 | 16 | 33 | 99 | 162 | 11 |
2 | GL-III-76 | Br | H | (S) | C-F | 83 | 3 | 0 | 100 | 221 | 120 |
3 | GL-III-36 | Br | H | (R) | C-F | 88 | 0 | 12 | 86 | 246 | 319 |
4 | KRM-II-18B | HC≡C | H | H | C-F | 89 | 11 | 20 | 97 | 361 | 38 |
5 | KRM-III-59 | Br | Me | H | C-F | 73 | 0 | 11 | 96 | 408 | 20 |
6 | GL-III-73 | HC≡C | H | (R) | C-F | 74 | 12 | 4 | 65 | 449 | 602 |
7 | GL-III-78 | HC≡C | H | (S) | C-F | 74 | 10 | 9 | 101 | 451 | 261 |
8 | KRM-II-73 | Br | H | H | C-H | 83 | 11 | 32 | 97 | 736 | 45 |
9 | KRM-III-66 | Br | Me | H | C-H | 67 | 12 | 11 | 86 | 756 | 49 |
10 | KRM-III-65 | HC≡C | Me | H | C-F | 64 | 0 | 16 | 96 | 879 | 45 |
11 | KRM-II-82 | HC≡C | H | H | C-H | 78 | 5 | 20 | 95 | 1203 | 96 |
12 | KRM-II-97 | Br | H | H | N | 62 | 18 | 8 | 93 | 1959 | 140 |
13 | KRM-III-67 | HC≡C | H | H | N | 48 | 30 | 3 | 71 | - 2 | 144 |
14 | KRM-II-81 | Br | Me | H | N | 46 | 7 | 15 | 86 | - 2 | 294 |
15 | KRM-III-79 | HC≡C | Me | H | N | 9 | 32 | 1 | 81 | - 2 | 308 |
1 Percent inhibition at 10,000 nM, 2 dose response was carried out only for compounds with an inhibition of >50%.